Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

BACKGROUND: Saracatinib (AZD0530) is an orally available Src kinase inhibitor. A phase II study was conducted to evaluate saracatinib in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). PATIENTS AND METHODS: This was an open-label, single-arm, phase II study. Patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Fury, Matthew G., Baxi, Shrujal, Shen, Ronglai, Kelly, Katherine W., Lipson, Brynna L., Carlson, Diane, Stambuk, Hilda, Haque, Sofia, Pfister, David G.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3705960/
https://ncbi.nlm.nih.gov/pubmed/21273606
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky